ACELRX PHARMACEUT. DL-01 Market Cap ($38.92 Million)
Market Cap & Net Worth: ACELRX PHARMACEUT. DL-01 (R5XA)
ACELRX PHARMACEUT. DL-01 market cap. ACELRX PHARMACEUT. DL-01 (F:R5XA) has a market capitalization of $38.92 Million (€33.29 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #22624 globally and #1993 in its home market, demonstrating a -3.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACELRX PHARMACEUT. DL-01's stock price €0.92 by its total outstanding shares 51899648 (51.90 Million). Also see R5XA operating cash flow for how efficiently the company converts equity into cash flow.
ACELRX PHARMACEUT. DL-01 Market Cap History (2015–2026)
ACELRX PHARMACEUT. DL-01 market cap history from 2015 to 2026. Data shows change from $4.13 Billion to $55.52 Million (-32.18% CAGR). Check R5XA stock price for real-time trading data and today's change.
ACELRX PHARMACEUT. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACELRX PHARMACEUT. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ACELRX PHARMACEUT. DL-01 annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1928.63x
ACELRX PHARMACEUT. DL-01's market cap is 1928.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $520.12 Million | $2.82 Million | -$35.10 Million | 184.57x | N/A |
| 2023 | $43.99 Million | $651.00K | -$18.40 Million | 67.57x | N/A |
| 2025 | $54.00 Million | $28.00K | -$14.29 Million | 1928.63x | N/A |
Competitor Companies of R5XA by Market Capitalization
Companies near ACELRX PHARMACEUT. DL-01 in the global market cap rankings as of November 4, 2026. Also see R5XA asset base for a full breakdown of the balance sheet.
Key companies related to ACELRX PHARMACEUT. DL-01 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of ACELRX PHARMACEUT. DL-01 (2015–2026)
Market capitalization of ACELRX PHARMACEUT. DL-01 from 2015 to today. Between 2015 and today, ACELRX PHARMACEUT. DL-01's market cap moved from $4.13 Billion to $ 55.52 Million, with a yearly change of -32.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €55.52 Million | +2.81% |
| 2025 | €54.00 Million | +79.07% |
| 2024 | €30.16 Million | -31.45% |
| 2023 | €43.99 Million | -62.93% |
| 2022 | €118.68 Million | -77.18% |
| 2021 | €520.12 Million | -54.57% |
| 2020 | €1.14 Billion | -51.94% |
| 2019 | €2.38 Billion | -6.08% |
| 2018 | €2.54 Billion | +30.62% |
| 2017 | €1.94 Billion | -36.41% |
| 2016 | €3.05 Billion | -26.00% |
| 2015 | €4.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ACELRX PHARMACEUT. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.92 Million USD |
| MoneyControl | $38.92 Million USD |
| MarketWatch | $38.92 Million USD |
| marketcap.company | $38.92 Million USD |
| Reuters | $38.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more